Bevacizumab for the treatment of recurrent glioblastoma.
about
Recent developments in receptor tyrosine kinases targeted anticancer therapyDynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel densityGlioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'Adaptation to antiangiogenic therapy in neurological tumorsLower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.Glioblastoma multiforme - an overview.Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.Antiangiogenic therapy for glioma.Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the nicheTumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Bevacizumab for glioblastoma: current indications, surgical implications, and future directionsBreast cancer brain metastases: new directions in systemic therapySafety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors.Anti-cancer Therapies in High Grade Gliomas.Antivascular endothelial growth factor antibody for treatment of glioblastoma multiformePseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Bevacizumab for the treatment of glioblastoma.Bevacizumab for glioblastoma-a promising drug or not?Assessment methods for angiogenesis and current approaches for its quantificationStandard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigensRindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme.Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.Investigational new drugs for brain cancer.Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.Temozolomide nanoparticles for targeted glioblastoma therapy.Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells.Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.Nanoparticles of carbon allotropes inhibit glioblastoma multiforme angiogenesis in ovo.Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer.
P2860
Q26751331-139F9F82-E624-4EF0-8228-0FB27F180B98Q27308856-9593B535-14D4-4E37-BE9A-2239D168BD4EQ28067399-4BEF6698-2BBF-4A32-8583-D98D5ECA866DQ28082908-D966B6E8-8C7D-4453-9CBA-BDB6C50090CBQ30831967-F43B5D3F-8561-4391-A8B8-306321D43D7CQ31131751-06C342B7-C7EE-45AD-B710-BE120358DEC0Q33625227-8833E898-F907-4676-9A92-73A560D9D9E3Q33668084-7A71BE0C-694B-41DC-BE79-F9FD4BD39BCCQ34417525-44852477-C486-4AD2-AD51-1D1C337ABE52Q34589068-C521B775-D941-4C9A-8E99-22DDDD14176EQ34978253-DC597F3F-B759-418B-95DF-FB0F35A545F9Q36101999-90FD3EB0-A090-4020-B044-95EE30AAC197Q36225175-9E819D41-729E-4D08-9B75-5FBFC789B89DQ36428702-837C61AE-C99C-425F-95F8-2F78E7F504AFQ36542980-17988210-6BB0-45DD-91D8-D8E51899B394Q36544122-E782C8CC-8E35-41E1-A3F5-018C0EE93604Q36785131-36C20F91-85ED-4B67-8885-118FF5C0CB50Q36822207-9094FCC9-117F-44C1-AB06-9C1AB75B0CF8Q36822500-12D3967D-72C6-45F7-AEC8-722A6E2BC50FQ36898626-B2DFF999-F393-43B7-A383-E941197A8570Q37290626-F8F77960-8A71-4168-AAD3-A76926EAE943Q37372416-6EABE27B-6912-4C2B-8E95-3248909745D1Q37591724-08CBE0CE-7A29-4A9C-8347-A02093476569Q38020234-255BACB7-1D9E-41E8-B4F8-CA2A21DD2377Q38129428-13A2600D-374D-4795-8A22-7527541DC8ADQ38161401-0F87A150-A87B-4217-8E64-3E1C8534B395Q38225523-1C2B12ED-6A81-4E0C-A3F5-870365F2ADD7Q38241483-97A39505-5678-4EE0-A1B6-F262ACC860C8Q38245925-BFC979B8-5495-4809-AC41-BB67B89F50B2Q38253056-0B493CC5-C312-495F-904A-2234D096C478Q38351134-B4E90629-52FB-4FF5-8FD1-27B455D66955Q38825960-76522013-3594-4BB1-B881-E35F2CA61B9CQ38832510-53573C26-0181-4F40-8EBB-4F0D57CE305CQ38897023-1313745A-2FC0-4CFA-B627-A12690642539Q38902260-9A8675FD-596C-4AA5-A66E-C1AE01D35CF8Q38984930-682FDD44-6EC9-47DB-86AD-398DD71FBBEBQ38985337-7899C0BE-D398-4BB9-A90A-BBD3A142767CQ39429294-752ADA55-5265-4D87-A55F-1FB2DADC2B52Q39597202-5445B5CC-A1D8-408A-8A1B-96060128882CQ40539652-A6E4A159-8135-4292-9F0D-6D947E73E6DD
P2860
Bevacizumab for the treatment of recurrent glioblastoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bevacizumab for the treatment of recurrent glioblastoma.
@ast
Bevacizumab for the treatment of recurrent glioblastoma.
@en
Bevacizumab for the treatment of recurrent glioblastoma.
@nl
type
label
Bevacizumab for the treatment of recurrent glioblastoma.
@ast
Bevacizumab for the treatment of recurrent glioblastoma.
@en
Bevacizumab for the treatment of recurrent glioblastoma.
@nl
prefLabel
Bevacizumab for the treatment of recurrent glioblastoma.
@ast
Bevacizumab for the treatment of recurrent glioblastoma.
@en
Bevacizumab for the treatment of recurrent glioblastoma.
@nl
P2860
P356
P1476
Bevacizumab for the treatment of recurrent glioblastoma.
@en
P2093
Marc C Chamberlain
P2860
P304
P356
10.4137/CMO.S7232
P407
P577
2011-05-02T00:00:00Z